Yecuris Overview
- Year Founded
-
2007
- Status
-
Private
- Employees
-
31
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Yecuris General Information
Description
Developer of chimeric animal models designed to provide researchers with actionable insights into liver-specific questions at the cellular, tissue, and animal level. The company promotes the use of chimeric animal technologies to answer critical questions in drug metabolism, clinical safety assessment, cancer biology, and gene and cell therapy, enabling researchers to find treatments and cures for metabolic and liver disorders ranging from cirrhosis and hepatitis to inborn errors and gene correction.
Contact Information
Website
www.yecuris.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
- P.O. Box 4645
- Tualatin, OR 97062
- United States
+1 (503) 000-0000
Yecuris Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 01-Apr-2023 | 000 | Completed | Generating Revenue | ||
| 4. Grant | 01-Jan-2014 | 00.000 | 000 | Completed | Generating Revenue | |
| 3. Early Stage VC | 00.000 | 000 | Completed | Generating Revenue | ||
| 2. Accelerator/Incubator | 01-Jan-2011 | $1.25M | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 15-Jul-2009 | $1.25M | $1.25M | 0000 | Completed | Generating Revenue |
Yecuris Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00 |
Yecuris Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of chimeric animal models designed to provide researchers with actionable insights into liver-specific questio
Biotechnology
Tualatin, OR
31
As of 2023
000
00000000000
000
000000
od tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam,
0000 000000000
Brighton, United Kingdom
00
As of 0000
0000
000000 - 000
0000
000000
t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitat
0000000000000
Montreal, Canada
0
As of 0000
00.000
0000000000 0
00.000
Add Comparison
Yecuris Competitors (18)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Enterprise Therapeutics | Venture Capital-Backed | Brighton, United Kingdom | 00 | 0000 | 000000 - 000 | 0000 |
| 0000000 000000 | Venture Capital-Backed | Montreal, Canada | 0 | 00.000 | 0000000000 0 | 00.000 |
| 000000 000000 | Corporation | London, United Kingdom | 00 | 00000 | 00000000 | 00000 |
| 0000 0000000 00000 | Corporation | Franklin, TN | 00 | |||
| 0000000 0000000000 | Formerly VC-backed | Westlake Village, CA | 000 | 00000 | 00000000 | 00000 |
Yecuris Patents
Yecuris Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2747551-A1 | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof | Active | 26-Aug-2011 | 00000000000 | |
| EP-2747551-A4 | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof | Active | 26-Aug-2011 | 00000000000 | 0 |
| EP-2747551-B1 | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof | Active | 26-Aug-2011 | 00000000000 | |
| EP-3578042-A1 | Fumarylacetoacetate hydrolase (fah)-deficient and immunodeficient rats and uses thereof | Inactive | 26-Aug-2011 | 00000000000 | 00 |
| ES-2791829-T3 | Rats deficient in fumarylacetoacetate hydrolase (fah) and immunodeficient and their uses | Active | 26-Aug-2011 | A01K67/0276 |
Yecuris Executive Team (5)
Yecuris Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Yecuris Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| U.S. Department of Health and Human Services | Government | 000 0000 | 000000 0 |